Quality Improvement

The NHS continues to strive to improve the detection and management of cardiovascular and kidney diseases, with an increased focus on CVD prevention.

These PCCS QI programmes aim to bring together the key components of delivering high quality cardiovascular and kidney care across general practice.

Please take a look at the relevant pages to look through our QI programmes on:

Chronic Kidney Disease
- This programme was solely funded by Bayer PLC. Bayer PLC were not involved in the development of the programme, content, selection of speakers or their arrangements. All content was independently developed by PCCS.
Lipid Management
- This programme has been solely funded by Novartis. Novartis were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by PCCS.
COVID-19 & CVD
- This programme has been funded by Pfizer Ltd by an independent medical educational grant. Pfizer were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by the PCCS.
Triglycerides
- This programme has been funded by Amarin Corp plc. Amarin were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by the PCCS.
Heart Failure
- This tool kit was developed in partnership with Salvera Services following financial support from AstraZeneca.